Drug intelligence / Profile preview

SND-479

Development stage: Preclinical
Lead developer: Floratek Pharma
Modality: Small Molecules

Overview

SND-479 is a plant-derived small molecule therapeutic being developed by Floratek Pharma for the treatment of solid tumors, specifically melanoma and colorectal cancer. The compound acts by modulating mitophagy and mitoptosis, which are specialized pathways for the degradation and programmed death of mitochondria. By targeting these mitochondrial quality control mechanisms, SND-479 is designed to disrupt cancer cell homeostasis and promote tumor cell death. As of 2024, the program is in the preclinical stage, with IND-enabling studies currently ongoing.

Other names: SND-479SND479SND 479

Beyond the preview

Go deeper on SND-479.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SND-479.

Explore the full profile